Katherine Helming Walsh
Helming KC, Wang X, Wilson BG et al. ARID1B is a specific vulnerability in ARID1A-mutant cancers. Nat Med. 2014; 20(3):251–254.
Helming KC, Wang X, Roberts CWM. Vulnerabilities of mutant SWI/SNF complexes in cancer. Cancer Cell. 2014;26(3):309–317.
Tolstorukov MY, Sansam CG, Lu P, Koellhoffer EC, Helming KC et al. Swi/Snf chromatin remodeling/tumor suppressor complex establishes nucleosome occupancy at target promoters. Proc Natl Acad Sci USA. 2013;110(25):10165–10170.
Katherine Helming Walsh, Ph.D.
Katherine Helming Walsh is the alliance manager for an industry-sponsored drug discovery collaborative project in oncology under the auspices of the Center for the Development of Therapeutics (CDoT) at the Broad Institute of MIT and Harvard. She is responsible for managing the relationship between the Broad Institute and the external partner, as well as supporting the development and progression of the joint scientific portfolio. In this role, she works to integrate the activities across a complex portfolio of projects to maximize success of both individual projects and the overall portfolio, with a goal of ultimate patient impact.
Prior to taking this post, Walsh was a member of the KRAS genetics team, which is a part of the KRAS initiative at Broad Institute aimed at identifying new therapeutic targets for KRAS mutant cancers. Her work there primarily focused on follow up from genome-wide CRISPR and shRNA screens. She joined the Broad Institute in 2015.
Walsh holds a Ph.D. in biological and biomedical sciences from Harvard Medical School, which she completed in the lab of Charles Roberts at Dana Farber Cancer Institute studying chromatin remodeling and cancer. During her doctoral studies, she also participated in the Leder Human Biology and Translational Medicine Program. In addition, she holds a B.S. from Providence College (summa cum laude) with a major in biology and a minor in Spanish.
Contact Katherine Helming Walsh at email@example.com.